InvestorLens

TEVA — TEVA PHARMACEUTICAL INDUSTRIES

Public company

Sign in to save7 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying TEVA?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
50
Institutional Conviction
Net distribution · 2 buying vs 2 selling last quarter
42
Macro Tailwind
Macro conditions are mixed for this sector
56
Congressional Activity
1 congressional purchase, 0 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 4 tracked investors who changed their TEVA position last quarter, 2 bought and 2 sold (50% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime). 1 congressional purchase, 0 sales disclosed in the last 6 months.

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Cathie Wood, Ray Dalio)
  • +7 tracked investors reported holding TEVA at their latest filing
  • +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (2 reduced, 0 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About TEVA PHARMACEUTICAL INDUSTRIES (TEVA)

TEVA PHARMACEUTICAL INDUSTRIES (TEVA) appears in the most recent 13F filings of 7 tracked institutional investors. The largest disclosed position is held by Stanley Druckenmiller (Duquesne Family Office), valued at $335M. Across recent filings, tracked investors recorded 8 new positions, 15 increased, 21 reduced, and 4 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in TEVA

48
/100
Mixed Activity
Added / Increased23
Reduced21
Exited4
BearishBullish
Crowded Trade Score™

How many top investors track TEVA

47
/100
Moderate Interest
7investors

Several tracked investors have exposure.

UndiscoveredCrowded
151015+

TEVA Ownership Composition

How TEVA PHARMACEUTICAL INDUSTRIES is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
64% of tracked value
Institutions
7
tracked investors
Total Reported
$515.7M
combined 13F value
Types3
  • Multi-Strategy / Quant64.3%
  • Value & Distressed19.0%
  • Macro16.8%
Multi-Strategy / Quant(3)
64.3%
Value & Distressed(1)
19.0%
Macro(3)
16.8%

Tracked investors currently reporting TEVA

1 tracked investor has since exited this position — listed separately below.

  • Stanley DruckenmillerJun 30, 2026
    Duquesne Family Office
    Shares
    625K
    Value
    $21.2M
    % Portfolio
    0.41%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    4.2M
    Value
    $143.7M
    % Portfolio
    0.02%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    4M
    Value
    $134.8M
    % Portfolio
    0.05%
  • David EinhornJun 30, 2026
    DME Capital Management, LP
    Shares
    2.9M
    Value
    $97.8M
    % Portfolio
    2.50%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    1.6M
    Value
    $53M
    % Portfolio
    0.06%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    1.3M
    Value
    $44.9M
    % Portfolio
    0.18%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    598.2K
    Value
    $20.3M
    % Portfolio
    0.03%

Previously held TEVA

These investors reported TEVA in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Andreas HalvorsenViking Global Investors2.5M$51.1MSep 30, 2025

Recent activity

Frequently asked questions

How many institutional investors hold TEVA?
7 tracked institutional investors disclosed a position in TEVA (TEVA PHARMACEUTICAL INDUSTRIES) in their most recent 13F filing.
Who is the largest institutional holder of TEVA?
Stanley Druckenmiller, Duquesne Family Office, holds the largest disclosed position in TEVA, valued at $335M.
Did institutional ownership of TEVA increase or decrease?
Across recent 13F filings, tracked investors recorded 8 new positions, 15 increased, 21 reduced, and 4 fully exited TEVA.
Where does this TEVA ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.